KẾT QUẢ BƯỚC ĐẦU VÀ CÁC YẾU TỐ LIÊN QUAN HÓA TRỊ TÂN BỔ TRỢ PHÁC ĐỒ PACLITAXEL-CARBOPLATIN UNG THƯ BIỂU MÔ BUỒNG TRỨNG GIAI ĐOẠN IIIC, IV TẠI BỆNH VIỆN K

Abstract

Background: Advanced-stage ovarian cancer (stages IIIC and IV) is often characterized by poor prognosis and significant progression, making initial surgery challenging. Neoadjuvant chemotherapy with the paclitaxel-carboplatin regimen has been shown to reduce tumor size, facilitating more effective surgery, potentially extending survival, and reducing intraoperative and postoperative complications. Subjects and Methods: A retrospective descriptive study included 52 ovarian cancer patients who received neoadjuvant treatment with the paclitaxel-carboplatin regimen at K Hospital from January 2017 to January 2023. Results: The average patient age was 55.3 ± 8.9. The most common presenting symptom was "abdominal pain and distention," seen in 80.7% of cases. Most patients had tumor sizes > 5 cm (86.5%), with stage IIIC cases accounting for 71.2%. The highest incidence subtype was serous adenocarcinoma (78.8%). The most common metastatic sites were retroperitoneal lymph nodes (25%), pleura (13.5%), and liver (13.5%). The majority of patients received > 90% of the standard chemotherapy dose (84.6%). Clinical response rates reached 100% after 3 cycles. Factors influencing treatment response were identified as chemotherapy dose, disease stage, and pleural effusion status. The most frequent adverse effects were hematologic, particularly leukopenia (45.2%), primarily grade I-II. Conclusion: The study demonstrates that neoadjuvant chemotherapy with the paclitaxel-carboplatin regimen improves response rates and extends survival in patients with stage IIIC and IV ovarian epithelial cancer. The findings also suggest an important role of neoadjuvant chemotherapy for certain groups of patients.